• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Does Elagolix Reduce Heavy Menstrual Bleeding Associated with Uterine Fibroids?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Elagolix is a GnRH antagonist that causes rapid, reversible suppression of ovarian sex hormones
    • It may reduce fibroid-associated bleeding
  • Schlaff et al. (NEJM, 2020) conducted two phase 3 trials to assess the efficacy and safety of elagolix for heavy menstrual bleeding due to fibroids

METHODS:

  • Two identical, double-blind, randomized, placebo-controlled, 6-month phase 3 trials
    • Elaris Uterine Fibroids 1 and 2 (UF-1 and UF-2)
  • Participants
    • Women with fibroid-associated bleeding
  • Interventions
    • Elagolix 300 mg twice daily with hormonal “add-back” therapy
      • Estradiol 1 mg, and norethindrone acetate 0.5 mg once daily
    • Elagolix-alone
    • Placebo
  • Primary outcome
    • Menstrual blood loss <80 ml during the final month of treatment
    • ≥50% reduction in menstrual blood loss from baseline to the final month

RESULTS:

  • 412 women in UF-1 | 378 women in UF-2
  • More women who received elagolix plus add-back therapy achieved the primary outcome than did women who received placebo (P<0.0001 for both studies)
    • Elagolix plus add-back therapy
      • UF-1: 68.5%
      • UF-2: 76.5%
    • Placebo
      • UF-1: 8.7%
      • UF-2: 10%
    • Elagolix-alone
      • UF-1: 84.1% 
      • UF-2: 77%
  • Comparing elagolix plus add-back therapy vs placebo, the following were increased
    • Hot flushes (in both trials)
    • Metrorrhagia (in UF-1)
  • Add-back therapy did improve hypoestrogenic effects of elagolix (e.g., decrease in bone mineral density)
  • Low rate of serious adverse events
    • No cases with drug-induced liver injury

CONCLUSION:

  • For women with uterine fibroids, elagolix was effective in reducing heavy menstrual bleeding
  • The authors state that

Since the trials were designed primarily to compare elagolix plus add-back therapy with placebo and prespecified a comparison of the two elagolix groups only with respect to bone mineral density, we cannot make conclusions regarding elagolix with add-back therapy as compared with elagolix alone with respect to the effects on other outcomes

Learn More – Primary Sources:

Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free  »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Another New Drug in the Pipeline to Treat Fibroids
IUD, Hysterectomy or Ablation for Menorrhagia?
How does TXA Measure Up as a Treatment for Menorrhagia?
Elaris EM-III and Elaris EM-IV Results: Long-Term Endometriosis Outcomes Following Administration of Elagolix

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site